NASDAQ: CARMCarisma Therapeutics Inc Stock
$1.71+0.02 (+1.18%)
Updated Apr 18, 2024
CARM Price
$1.71
Fair Value Price
N/A
Market Cap
$71.04M
52 Week Low
$1.65
52 Week High
$9.77
P/E
-0.66x
P/B
2.68x
P/S
6.58x
PEG
N/A
Dividend Yield
N/A
Revenue
$14.92M
Earnings
-$86.88M
Gross Margin
100%
Operating Margin
-595.31%
Profit Margin
-582.3%
Debt to Equity
2.38
Operating Cash Flow
-$81M
Beta
1
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
CARM Overview
Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics, Inc. has a strategic collaboration agreement with Moderna Inc. Carisma Therapeutics, Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CARM scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CARM is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CARM is good value based on its book value relative to its share price (2.68x), compared to the US Biotechnology industry average (5.76x)
P/B vs Industry Valuation
CARM is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 35 more CARM due diligence checks available for Premium users.
Be the first to know about important CARM news, forecast changes, insider trades & much more!
CARM News
Valuation
CARM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.66x
Industry
15.68x
Market
41.33x
CARM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.68x
Industry
5.76x
CARM is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CARM's financial health
Profit margin
Revenue
$4.3M
Net Income
-$21.0M
Profit Margin
-488.6%
CARM's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CARM's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$89.6M
Liabilities
$63.0M
Debt to equity
2.38
CARM's short-term assets ($80.47M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CARM's short-term assets ($80.47M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CARM's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CARM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$16.1M
Investing
$10.4M
Financing
$101.0k
CARM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CARM vs Biotech Stocks
Carisma Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.